• By ICR Secretariat
  • Posted Monday, September 5, 2022

US earmarks up to $680M for Chimerix's smallpox drug Tembexa, clearing way for Emergent buyout

https://www.fiercepharma.com/pharma/us-government-earmarks-680m-chimerixs-smallpox-drug-tembexa-clears-way-emergents-buyout

During the latest monkeypox outbreak, doctors in the U.S. have been treating patients with Siga Technologies’ smallpox drug Tpoxx. Now, the U.S. government may have a second potential antiviral option at its disposal.